We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J (JNJ) Seeks Stelara Label Expansion in Juvenile Arthritis
Read MoreHide Full Article
Johnson & Johnson’s (JNJ - Free Report) pharmaceutical company, Janssen announced that it has submitted a supplemental biologics license application (sBLA) for inflammatory drug, Stelara, to the FDA. The sBLA is seeking the label expansion of the drug as a potential treatment of juvenile psoriatic arthritis (jPsA) in pediatric patients aged 5 years and older. The company anticipates the FDA to provide its decision in late 2022, following a potential acceptance.
The sBLA has been filed based on extrapolated data from nine clinical studies that evaluated Stelara in adults with active PsA, and in adult and pediatric patients with moderate-to-severe plaque psoriasis. The extrapolated data includes an estimated response, trends or effects of a drug or candidate based on historical observations from patients with closely related conditions. This type is used when there is limited availability of pediatric patients.
Stelara is currently approved as a treatment of several inflammatory disorders namely plaque psoriasis, active PsA, active Crohn’s disease, and active ulcerative colitis in adults. The drug is also approved for treating plaque psoriasis in pediatric patients aged six months or older.
The juvenile PsA is a disorder characterized by joint inflammation and psoriatic skin lesions similar to PsA in adults and is a challenging disease to treat. Per the company release, jPsA occurs in a small patient population, affecting only 5% of juvenile arthritis patients. This condition occurs in an estimated 20 to 45 children for every 100,000 children in the United States.
This year so far, J&J’s shares have risen 2.2% compared with an increase of 9% for the industry.
Image Source: Zacks Investment Research
We note that Stelara is the largest drug of J&J’s immunology franchise that generated sales of $4.4 billion in the first half of 2021, registering growth of 25.8% year over year. The drug is one of the key products that helped J&J to deliver above-market growth for the pharmaceutical business in 2021. The strong performance of the drug will receive a boost following a potential approval to treat the challenging jPsA.
Meanwhile, J&J is evaluating Stelara as a potential treatment for axial spondylitis in phase III studies.
Vertex’s earnings per share estimates have moved north from $12.28 to $12.37 for 2021 and from $13.02 to $13.13 for 2022 over the past 60 days.
Regeneron’s earnings estimates have been revised upward from $53.22 to $61.41 for 2021 and from $44.11 to $46.73 for 2022 over the past 60 days. The stock has increased 13.9% year to date.
Horizon’s earnings per share estimates have increased from $4.46 to $4.67 for 2021 and from $5.84 to $6.23 for 2022 over the past 60 days. The stock has rallied 55.6% year to date.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
J&J (JNJ) Seeks Stelara Label Expansion in Juvenile Arthritis
Johnson & Johnson’s (JNJ - Free Report) pharmaceutical company, Janssen announced that it has submitted a supplemental biologics license application (sBLA) for inflammatory drug, Stelara, to the FDA. The sBLA is seeking the label expansion of the drug as a potential treatment of juvenile psoriatic arthritis (jPsA) in pediatric patients aged 5 years and older. The company anticipates the FDA to provide its decision in late 2022, following a potential acceptance.
The sBLA has been filed based on extrapolated data from nine clinical studies that evaluated Stelara in adults with active PsA, and in adult and pediatric patients with moderate-to-severe plaque psoriasis. The extrapolated data includes an estimated response, trends or effects of a drug or candidate based on historical observations from patients with closely related conditions. This type is used when there is limited availability of pediatric patients.
Stelara is currently approved as a treatment of several inflammatory disorders namely plaque psoriasis, active PsA, active Crohn’s disease, and active ulcerative colitis in adults. The drug is also approved for treating plaque psoriasis in pediatric patients aged six months or older.
The juvenile PsA is a disorder characterized by joint inflammation and psoriatic skin lesions similar to PsA in adults and is a challenging disease to treat. Per the company release, jPsA occurs in a small patient population, affecting only 5% of juvenile arthritis patients. This condition occurs in an estimated 20 to 45 children for every 100,000 children in the United States.
This year so far, J&J’s shares have risen 2.2% compared with an increase of 9% for the industry.
We note that Stelara is the largest drug of J&J’s immunology franchise that generated sales of $4.4 billion in the first half of 2021, registering growth of 25.8% year over year. The drug is one of the key products that helped J&J to deliver above-market growth for the pharmaceutical business in 2021. The strong performance of the drug will receive a boost following a potential approval to treat the challenging jPsA.
Meanwhile, J&J is evaluating Stelara as a potential treatment for axial spondylitis in phase III studies.
Johnson & Johnson Price
Johnson & Johnson price | Johnson & Johnson Quote
Zacks Rank & Stocks to Consider
J&J currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the pharma/biotech sector include Vertex Pharmaceuticals (VRTX - Free Report) , Regeneron Pharmaceuticals (REGN - Free Report) and Horizon Therapeutics , all sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vertex’s earnings per share estimates have moved north from $12.28 to $12.37 for 2021 and from $13.02 to $13.13 for 2022 over the past 60 days.
Regeneron’s earnings estimates have been revised upward from $53.22 to $61.41 for 2021 and from $44.11 to $46.73 for 2022 over the past 60 days. The stock has increased 13.9% year to date.
Horizon’s earnings per share estimates have increased from $4.46 to $4.67 for 2021 and from $5.84 to $6.23 for 2022 over the past 60 days. The stock has rallied 55.6% year to date.